In contrast, mice treated with the tritherapy (anti-GITR, anti-PD-1 and peritumoral BMCs) demonstrated the best efficacy with tumor growth further delayed (median survival of 41 days) and 19.3% complete tumor regression. The gene discussed is PDCD1; the disease is neoplasm.